Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Nancy A. Noble"'
Autor:
Nancy L. Noble, Nancy L. Sweeney
Publikováno v:
Workplace Health & Safety. 66:41-48
Work-related musculoskeletal disorders (WMSD) are a major safety concern in today’s health care environment due to the manual lifting of patients with higher acuity levels and obesity. Nurses move patients multiple times each day, incurring cumulat
While angiotensin II blockade slows the progression of diabetic nephropathy, current data suggest that it alone cannot stop the disease process. New therapies or drug combinations will be required to further slow or halt disease progression. Inhibiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9856067ec3fd770a7ee908e0132d2129
https://europepmc.org/articles/PMC5130463/
https://europepmc.org/articles/PMC5130463/
Publikováno v:
American Journal of Physiology-Renal Physiology. 303:F11-F20
While elevated plasma prorenin levels are commonly found in diabetic patients and correlate with diabetic nephropathy, the pathological role of prorenin, if any, remains unclear. Prorenin binding to the (pro)renin receptor [(p)RR] unmasks prorenin ca
Publikováno v:
American Journal of Physiology-Renal Physiology. 298:F579-F588
Recent identification of a counterregulatory axis of the renin-angiotensin system, called angiotensin-converting enzyme 2-angiotensin-(1–7) [ANG-(1–7)]-Mas receptor, may offer new targets for the treatment of renal fibrosis. We hypothesized that
Publikováno v:
American Journal of Physiology-Renal Physiology. 297:F1045-F1054
Administration of a mutant, noninhibitory PAI-1 (PAI-1R), reduces disease in experimental glomerulonephritis. Here we investigated the importance of vitronectin (Vn) binding, PAI-1 stability and protease binding in this therapeutic effect using a pan
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 295:E810-E819
Although elevated plasma prorenin levels are commonly found in diabetic patients and correlate with microvascular complications, the pathological role of these increases, if any, remains unclear. Prorenin/renin binding to the prorenin/renin receptor
Publikováno v:
American Journal of Physiology-Renal Physiology. 294:F1287-F1295
Aldosterone is thought to modulate renal fibrosis, in part, through increasing plasminogen activator inhibitor type 1 (PAI-1), a major inhibitor of ECM degradation. The present study investigated aldosterone effects on PAI-1 and transforming growth f
Publikováno v:
Journal of the American Society of Nephrology. 19:329-338
Plasminogen activator inhibitor-1 (PAI-1) has been implicated in renal fibrosis. In vitro, PAI-1 inhibits plasmin generation, and this decreases mesangial extracellular matrix turnover. PAI-1R, a mutant PAI-1, increases glomerular plasmin generation,
Autor:
Nancy A. Noble, Yufeng Huang
Publikováno v:
Current Drug Targets. 8:1007-1015
Fibrotic renal diseases represent a major health care problem because of their prevalence and the fact that available therapies merely slow, but do not halt progression to renal failure. New therapies to further slow or stop the progression to end st
Publikováno v:
Kidney International. 72:45-52
Recent evidence indicates that renin itself might be profibrotic, independent of angiotensin II; however, the signaling system by which renin exerts a direct effect is not known. We tested the hypothesis that renin receptor activation, in turn, activ